FDA Warning Letter: Avoidance and Advice

Abstract

Summary This article provides an advisory approach regarding how to avoid an FDA Warning Letter following the receipt of a significant Form FDA 483. The focus is on the 483 response as it applies to GCP but can be applied to the response to the Warning Letter itself as well as a wider scope of GXP (GMP, GLP, GCP) inspection and audit responses. Copyright © 2011 John Wiley & Sons, Ltd.